Medipharm Labs Corp
TSX:LABS
Gross Margin
Medipharm Labs Corp
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| CA |
|
Medipharm Labs Corp
TSX:LABS
|
29.1m CAD |
30%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
731.4B USD |
82%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
56%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
393.8B USD |
68%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.8T DKK |
84%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
205.6B CHF |
74%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
180.8B CHF |
76%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
159.6B GBP |
82%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
201.2B USD |
78%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
68%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
139.1B USD |
75%
|
Medipharm Labs Corp
Glance View
MediPharm Labs Corp. is medicinal cannabis company, which engages in the pharmaceutical grade production of cannabis oil products. The company is headquartered in Barrie, Ontario and currently employs 190 full-time employees. The company went IPO on 2018-02-09. The firm produces purified, pharmaceutical-like cannabis extracts and related derivative products. The firm formulates, processes, packages and distributes cannabis extracts and cannabinoid-based products at its Canadian and Australian facilities for domestic and international markets. The Company, through its subsidiaries is engaged in the sale and distribution of cannabis oil, cannabis extracts, cannabis edibles, cannabis topicals, and derivatives to authorized classes of purchasers, as well as controlled human administration trials for sensory testing of cannabis extracts and derivative products. The company is also engaged in the manufacturing of extracts and tinctures of cannabis and cannabis resin for the purpose of a clinical trial or prescribed as medical cannabis products. The firm's wholly owned subsidiaries include MediPharm Labs Inc. and MediPharm Labs Australia Pty. Ltd.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Medipharm Labs Corp's most recent financial statements, the company has Gross Margin of 30.3%.
You don't have any saved screeners yet